The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
However, not all companies with momentum are long-term winners, and many investors have lost money by following short-term trends. All that said, here are three stocks that are likely overheated and some you should look into instead.
Twilio (TWLO)
One-Month Return: +28.7%
Known for the clever "Twilio Magic" demo that had developers creating functioning communications apps in minutes, Twilio (NYSE: TWLO) provides a platform that enables businesses to communicate with their customers through voice, messaging, email, and other digital channels.
Why Do We Think Twice About TWLO?
- Struggled to drive increased usage of its software, demonstrated by its subpar 110% net revenue retention rate
- Gross margin of 48.7% is way below its competitors, leaving less money to invest in areas like marketing and R&D
- Operating margin expanded by 4.3 percentage points over the last year as it scaled and became more efficient
Twilio is trading at $183.50 per share, or 5x forward price-to-sales. Check out our free in-depth research report to learn more about why TWLO doesn’t pass our bar.
Ford (F)
One-Month Return: +19.3%
Established to make automobiles accessible to a broader segment of the population, Ford (NYSE: F) designs, manufactures, and sells a variety of automobiles, trucks, and electric vehicles.
Why Do We Pass on F?
- Annual sales growth of 3.4% over the last two years lagged behind its industrials peers as its large revenue base made it difficult to generate incremental demand
- Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
- 8× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
Ford’s stock price of $14.90 implies a valuation ratio of 10x forward P/E. To fully understand why you should be careful with F, check out our full research report (it’s free).
Integra LifeSciences (IART)
One-Month Return: +41.3%
Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.
Why Should You Dump IART?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Incremental sales over the last five years were much less profitable as its earnings per share fell by 2.4% annually while its revenue grew
- 5× net-debt-to-EBITDA ratio makes lenders less willing to extend additional capital, potentially necessitating dilutive equity offerings
At $15.10 per share, Integra LifeSciences trades at 6.1x forward P/E. Dive into our free research report to see why there are better opportunities than IART.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
